MAGL-IN-22
MAGL-IN-22 (Compound 40) is a reversible, competitive, selective and BBB-penetrable MAGL inhibitor with an IC50 of 0.34 μM for hMAGL. MAGL-IN-22 has significant antioxidant and anti-inflammatory activity, and activates the Nrf2 pathway and significantly inhibits NFκB-mediated inflammation, without inducing cytotoxic effects. MAGL-IN-22 can be used for neurodegenerative diseases, chronic pain and cancers research[1].
Product Specifications
CAS Number
2720674-71-3
UNSPSC
12352005
Target
Keap1-Nrf2; MAGL; NF-κB
Related Pathways
Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Smiles
O=C(CCCC1=CC=CC=C1)NC2=C(C=CC(C3=CC(F)=C(C=C3)O)=C2)O
Molecular Formula
C22H20FNO3
Molecular Weight
365.40
References & Citations
[1]Bononi G, et al. Discovery of reversible monoacylglycerol lipase (MAGL) inhibitors based on ortho-hydroxyanilide scaffold. Bioorg Chem. 2025 Aug;163:108698.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740634-100 1x 100 µL
CD146 / MCAM / MUC18 / Mucin 18 (C146/634), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC742808-100 1x 100 µL
Cytokeratin 18 (KRT18) (KRT18/2808R), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details